Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2425 participants.

Also called NCT03790800

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,425 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03790800
Other papers using this trial's data
  • Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke The New England journal of medicine, 2024-05-30 DOI, PubMed 38752650

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03790800. Randomized; single masking; primary purpose treatment. Start 2020-03-20 (actual); primary completion 2023-11-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial
Acronym
INTERACT4
Condition
Stroke, Acute
Condition
Cerebrovascular Disorders
Intervention (Drug)
urapidil
Lead sponsor
The George Institute for Global Health, China (class: other)
Collaborator
Shanghai East Hospital (class: other)
Collaborator
First Affiliated Hospital of Chengdu Medical College (class: other)
Collaborator
Sichuan Academy of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct03790800
Content hash
dd34badd4e6916ee5032a847dfe1503e968126e828946e1503748d65f48ffb22